arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xenon Pharmaceuticals Inc.

XENE
$37.70 ▼ -1.48 (-3.79%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xenon Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.8B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -9.9% ↘
FCF / Share $-0.96 ↗
Trailing P/E —
Price / Book 2.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-102.30M
↓ -57.3% —
Operating Margin Operating profit as % of sales
-198.1%
↓ -3.2% —
FCF / Share Free cash flow per share
$-0.96
↑ +5.8% —
Long-Term Debt Long-term obligations
$10.89M
↓ -7.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
14
Cash Quality ↓
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 55 quarters